<DOC>
	<DOCNO>NCT00701506</DOCNO>
	<brief_summary>The purpose study investigate benefit Patterned Neuromuscular Electrical Stimulation ( PENS ) treatment osteoarthritis . The rationale investigation ass benefit PENS alleviation symptom osteoarthritis elucidate mechanism action PENS .</brief_summary>
	<brief_title>Patterned Electrical Neuromuscular Stimulation Therapeutic Exercise Osteoarthritis Knee : Pilot Study</brief_title>
	<detailed_description>There two study condition ; patient assign PENS treatment control group . Study arm 1 - 15 Patients ( may expand ) receive stimulation follow parameter : - 20-minute session , affect knee , 3 time per week 12 week . - PENS 20 minute : - Tri-phasic Lower Extremity stimulation pattern base activation time quadriceps hamstring strength training ( 50 Hz impulse 200 m every 1500 m ) . - Minimal twitch 5 minute . - Moderate strong , well-tolerated twitch contraction 15 minute . - Electrodes place quadriceps hamstring . Study arm 2 - 5 Patients ( may expand ) receive stimulation follow parameter : - 20-minute session , affect knee , 3 time per week 12 week . - Placebo PENS 20 minute : - Electrodes place quadriceps hamstring . A previous study perform principal investigator compare treatment knee osteoarthritis exercise v control group . The data study use historically compare exercise PENS treatment . Primary Endpoints The follow endpoint evaluate ( within group ) : Change WOMAC osteoarthritis-specific status baseline end treatment phase ( 12 week ) ; Change VAS . Secondary Endpoints The follow endpoint evaluate : Change biochemical Synovial Fluid marker baseline end treatment phase ( 12 week ) ; MRI Data ; Muscle strength ; Change pressure algometry knee joint ; Change patient self-reported physician-reported global assessment baseline end treatment ( 12 week ) ; Change pain intensity baseline end treatment phase ( 12 week ) ; Change physical function index baseline end treatment phase ( 12 week ) ; Number patient report 20 % improvement pain intensity ; Number patient record 20 % improvement self-reported osteoarthritis overall questionnaire score ; Number patient indicate 20 % improvement self-reported physician-reported global assessment score . Other Observations The follow also monitor : Changes prescription over-the-counter medication usage ( type use amount take ) ; Adherence treatment protocol ( data clinical treatment record ) ; Safety electrical stimulation knee aspiration . Primary Outcomes : Primary outcome study osteoarthritis-specific functioning , ( WOMAC ) . Osteoarthritis-specific functioning evaluate Western Ontario McMaster Universities Osteoarthritis Index version 3.1 ( WOMAC 3.1 ) . The WOMAC 3.1 24-item patient self-reported questionnaire assess pain , stiffness , physical function disability . The WOMAC available Japanese version . Pain intensity measure use 10-centimeter visual analog scale ( VAS scale ) . The scale anchor one end `` 0 '' label `` pain , '' `` 10 '' label `` bad pain possible . '' Secondary Outcomes : Secondary outcome study pain intensity , global assessment function , physical functioning safety . Biochemical marker knee joint fluid evaluate change related electrical stimulation . Synovial fluid aspirate , baseline 12 week electrical stimulation , osteoarthritic knee receive stimulation . Fluid volume acidity ( i.e. , pH ) , chondroitin 6-sulfate chondroitin 4-sulfate concentration , hyaluronan ( concentration , molecular weight viscosity ) assess . Chondroitin sulfate isomer evaluate use high performance liquid chromatography . Hyaluronan viscosity determine use capillary viscometer , molecular weight determine viscosity , concentration protein assay . MRI take evaluate volume muscle group , thickness cartilage , glucosaminoglycan content Global assessment function address single question ; one patient one treating physician . On 10 cm visual analogue scale follow similarly word question rat : Considering way OA impact life { patient 's life } last month , would rate { patient 's } condition today ? The scale anchor one end `` 0 '' label `` poor , '' end `` 10 '' label `` good . '' Physical performance ( objectively measure data ) assess use time up-and-go test . Quadriceps strength evaluate use mechanical dynamometer . Muscle strength conduct prior physical performance measure reduce bias due fatigue . Responses questionnaire obtain prior physical measurement , physician aspirate treat knee . Prescription medication regimen patient report physician study coordinator . The patient report over-the-counter medication use . Patient adherence stimulation protocol monitor clinical record . Safety electrostimulation fluid aspiration procedure monitor via adverse event report physician study coordinator . Serious adverse event ( i.e. , fatal , life threatening , need hospitalization ) anticipate electrostimulation aspiration knee . Anticipated adverse event electrostimulation minor ( e.g. , skin irritation ) , knee aspiration adverse event may include knee pain , swell , stiffness , vasovagal syncopal reaction .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Patient may evidence osteoarthritis ( radiographic and/or patient symptom report ) one joint , however , osteoarthritis one knee patient 's primary complaint focus treatment . Radiographic evidence , within 6 month enrollment , osteoarthritis knee receive treatment . Kellgren Lawrence osteoarthritis classification grade 1 , 2 3 ( i.e. , indicative cartilage still remain joint ) . Average rating pain associate osteoarthritis knee great equal 4 cm ( 10 cm visual analog scale ) . Stiffness knee ( ) last less 30 minute ( demonstrate stiffness serious condition ) Agrees follow randomize treatment plan use device . At least 18 year old . Signed informed consent . Erythrocyte Sedimentation rate great 40 mm/hour ( Higher rate may indicative RA ) Agrees follow randomize treatment plan use stimulation device . Hypersensitivity electrical stimulation . Undergone within 3 month enrollment , corticosteroid viscosupplementation ( i.e. , hyaluronate ) injection effect knee . If take medication oral steroid , nonsteroidal antiinflammatories , acetaminophen , patient stable dose least 3 month prior enrollment . ( The criterion match prior retrospective data study . ) If take chondroprotective supplement ( e.g. , glucosamine chondroitin sulfate ) , patient stable dose least 3 month prior enrollment . Pathologic process knee ( congenital defect blunt trauma lead structural defect tear anterior cruciate meniscus ligament ) . Problems due mechanical/anatomical deformity ( i.e. , valgus great 5 degree varus great 1.5 degree ) Women , plan become pregnant clinical investigation . Known malignancy cancer . Morbid obesity ( BMI &gt; 40 ) . Serious uncontrolled systemic illness ( e.g. , autoimmune disease , rheumatoid arthritis , diabetes mellitus renal failure ) . Implanted device cardiac pacemaker defibrillator Concurrent use another electrical stimulation device treatment knee symptom . Ongoing enrollment , discontinue enrollment within last 30 day , another clinical trial medical device biologic agent . Relationship medical ( e.g. , spouse employee investigator ) principal investigator ( ) staff may bias patient report . Relationship another person enrol clinical investigation . Unable complete study per investigational plan unable complete case report form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Knee</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Treatment</keyword>
	<keyword>Electrostimulation</keyword>
</DOC>